Shenzhenlubris Pharmaceuticals Co (SZSE:002294) EPS (Basic) : ¥0.51 (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co EPS (Basic)?

Shenzhenlubris Pharmaceuticals Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was ¥0.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.51.

Shenzhenlubris Pharmaceuticals Co's EPS (Diluted) for the three months ended in Mar. 2024 was ¥0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.51.

Shenzhenlubris Pharmaceuticals Co's EPS without NRI for the three months ended in Mar. 2024 was ¥0.18. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was 0.55.

During the past 12 months, Shenzhenlubris Pharmaceuticals Co's average EPS without NRIGrowth Rate was -6.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 389.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was -18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Shenzhenlubris Pharmaceuticals Co's highest 3-Year average EPS without NRI Growth Rate was 389.80% per year. The lowest was -85.60% per year. And the median was 26.20% per year.

Shenzhenlubris Pharmaceuticals Co EPS (Basic) Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co EPS (Basic) Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

0.68

0.06

0.50

0.58

0.52

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															0.19	0.11	0.13	0.09	0.18

Shenzhenlubris Pharmaceuticals Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Shenzhenlubris Pharmaceuticals Co's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(580.066	-	0)	/	1115.512
	=	0.52

Shenzhenlubris Pharmaceuticals Co's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(200.265	-	0)	/	1112.585
	=	0.18

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.51

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Shenzhenlubris Pharmaceuticals Co EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines